USANA's Steep Slide: Why Analysts Are Looking Elsewards Amid Revenue and EPS Declines
Shares of nutritional supplements maker USANA have tumbled over 25% in six months, trading near $21.66. While the valuation appears reasonable, underlying weaknesses in revenue growth and profitability are prompting investors to consider alternatives.